

**UNITED STATES SECURITIES AND EXCHANGE  
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**

**OMB APPROVAL**

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Rodino-Klapac Louise</u>  (Last) (First) (Middle) <u>215 FIRST STREET</u>  (Street) <u>CAMBRIDGE MA</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>12/14/2020</u>	3. Issuer Name and Ticker or Trading Symbol <u>Sarepta Therapeutics, Inc. [ SRPT ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Scientific Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>7,169</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Option (right to buy)</u>	<u>04/30/2019<sup>(1)</sup></u>	<u>04/30/2028</u>	<u>Common Stock</u>	<u>28,875</u>	<u>76.36</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>03/04/2020<sup>(1)</sup></u>	<u>03/04/2029</u>	<u>Common Stock</u>	<u>2,748</u>	<u>145.48</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>03/04/2020<sup>(1)</sup></u>	<u>03/04/2029</u>	<u>Common Stock</u>	<u>37,252</u>	<u>145.48</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>02/28/2021<sup>(1)</sup></u>	<u>02/28/2030</u>	<u>Common Stock</u>	<u>873</u>	<u>114.47</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>02/28/2021<sup>(1)</sup></u>	<u>02/28/2030</u>	<u>Common Stock</u>	<u>36,627</u>	<u>114.47</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>02/28/2021<sup>(1)</sup></u>	<u>02/28/2030</u>	<u>Common Stock</u>	<u>25,000</u>	<u>114.47</u>	<u>D</u>	

**Explanation of Responses:**

1. Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter.

**Remarks:**

/s/ Louise Rodino-Klapac 12/14/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**